Latest news with #AustralianMarket
News.com.au
8 hours ago
- Automotive
- News.com.au
2025 Hyundai Inster electric car review
Cheap Chinese cars have flooded the Australian market in the past few years – now the established automotive empire is striking back. The Hyundai Inster has just arrived in Australia and is the cheapest new electric vehicle you can buy that's not built by a new Chinese brand (and not a very old Nissan Leaf). This is a significant moment for the establishment, as Chinese brands including BYD, GWM and MG have made massive inroads into the Australian market, largely thanks to aggressive pricing that has simply been too good for buyers to ignore. The catch is, despite being the cheapest non-Chinese model, the Inster is still more expensive than its direct rivals – and not by a small margin. The Inster Standard Range model is priced from $39,900 (plus on-road costs), which puts it well above the $29,990 drive-away BYD Dolphin and $33,990 drive-away GWM Ora. While the extra asking price doesn't bring more size, it does bring Hyundai's reputation and experience – something none of its rivals can compete with. Hyundai has spent more than three decades building up a reputation for value, dependability and, in recent years, some of the most dynamically capable cars on the market (thanks to its local suspension and steering tuning program). Hyundai has also invested heavily in design, and there's no question from the moment you lay eyes on the Inster, this is a more thoughtful and more premium offering than its Chinese challengers. Instead of being shaped for less resistance through the air, Hyundai has given the Inster the find of fun, funky face that it hopes younger buyers will be drawn to. The clever design carries over to the interior, where Hyundai has managed to liberate a surprising amount of space for such a pint-sized car. Remarkably, it manages to have more interior space than the bigger (petrol-powered) Venue small SUV, with enough room to fit four adults in relative comfort. The catch is, the boot is quite small, but Hyundai has come up with a solution for that – the Inster Cross. This is a more 'adventure-focused' (Hyundai's words, not ours) version that has a more powerful engine and is more expensive but is available with a roof basket as a no-cost option. The full line-up consists of the Inster Standard Range, Extended Range and the Cross (both $45,000 plus on-road costs). The Standard Range is powered by a 71kW/147Nm front-mounted motor, paired to a 42kWh battery that provides up to 327km range. The Extended Range and Cross get an 84kW/147Nm motor as well as a bigger 49kWh battery, which takes the range to 360km range (although if you add the roof basket to the Cross the official range drops to 293km, but you can get it without the basket and with a sunroof instead). While none of those figures scream 'hot hatch' the Inster is surprisingly fun to drive. Its compact dimensions and relatively long wheelbase means it feels agile but stable either zippy through traffic or on a winding road. And this is another area where it justifies the extra money, because it feels more enjoyable and interesting to drive than any of its Chinese peers, but it also pulls up hills with more ease than a petrol-powered car of this size. Whether or not that's enough to lure many buyers, particularly the younger buyers Hyundai is hoping for, remains difficult to foresee. Electric vehicle sales have cooled off dramatically in the past year, so the Inster is facing multiple challenges to success. But Hyundai has laid down a marker with this car, it may not be quite as cheap as the Chinese competition, but it's close enough to be competitive. HYUNDAI INSTER
Yahoo
14 hours ago
- Business
- Yahoo
ASX Penny Stocks To Consider In June 2025
The Australian market is experiencing some turbulence, with futures indicating a slight decline for the ASX 200, largely influenced by ongoing international trade uncertainties. Despite these fluctuations, investors continue to seek opportunities in various sectors, including the often-overlooked realm of penny stocks. Although the term 'penny stocks' might seem outdated, these smaller or newer companies can offer unique opportunities for growth and value when supported by solid financials. Name Share Price Market Cap Financial Health Rating Lindsay Australia (ASX:LAU) A$0.71 A$225.19M ★★★★☆☆ CTI Logistics (ASX:CLX) A$1.85 A$149.01M ★★★★☆☆ Accent Group (ASX:AX1) A$1.90 A$1.14B ★★★★☆☆ EZZ Life Science Holdings (ASX:EZZ) A$1.565 A$73.83M ★★★★★★ IVE Group (ASX:IGL) A$2.55 A$393.16M ★★★★★☆ GTN (ASX:GTN) A$0.61 A$116.42M ★★★★★★ Bisalloy Steel Group (ASX:BIS) A$3.50 A$166.08M ★★★★★★ Regal Partners (ASX:RPL) A$2.33 A$783.26M ★★★★★★ Tasmea (ASX:TEA) A$2.99 A$699.78M ★★★★★☆ SHAPE Australia (ASX:SHA) A$3.29 A$272.21M ★★★★★★ Click here to see the full list of 1,000 stocks from our ASX Penny Stocks screener. Here we highlight a subset of our preferred stocks from the screener. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix technology in the United States and internationally, with a market cap of A$175.90 million. Operations: Revenue Segments: No specific revenue segments have been reported for Aroa Biosurgery Limited. Market Cap: A$175.9M Aroa Biosurgery has demonstrated notable progress, with sales reaching NZ$84.7 million for the year ending March 31, 2025, reflecting an increase from the previous year. Despite a net loss of NZ$3.81 million, this marks an improvement from prior losses. The company is debt-free and maintains a strong cash position with short-term assets surpassing liabilities significantly, ensuring a stable financial runway for over three years. Recent clinical evidence highlights the efficacy of its Endoform Natural product in treating venous leg ulcers more effectively than competitors, potentially enhancing patient outcomes and reducing costs in wound care management. Click to explore a detailed breakdown of our findings in Aroa Biosurgery's financial health report. Examine Aroa Biosurgery's earnings growth report to understand how analysts expect it to perform. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Baby Bunting Group Limited operates as a retailer of maternity and baby goods in Australia and New Zealand, with a market cap of A$233.41 million. Operations: The company generates A$496.90 million in revenue from its specialty retail segment. Market Cap: A$233.41M Baby Bunting Group's financial position is mixed, with a market cap of A$233.41 million and revenue of A$496.90 million from its specialty retail segment. The company faces challenges, such as negative earnings growth over the past year and declining profit margins, currently at 1.2%. Despite these issues, Baby Bunting maintains a satisfactory net debt to equity ratio of 8.6%, with debt well covered by operating cash flow at 177.9%. However, short-term assets do not cover long-term liabilities (A$132 million), and interest coverage by EBIT is low at 2.2x, indicating potential financial strain ahead. Jump into the full analysis health report here for a deeper understanding of Baby Bunting Group. Explore Baby Bunting Group's analyst forecasts in our growth report. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: COSOL Limited, along with its subsidiaries, offers information technology services across the Asia Pacific, North America, Europe, the Middle East, Africa, and globally with a market cap of A$142.86 million. Operations: The company generates revenue primarily from its Asia Pacific operations, contributing A$98.75 million, and North American activities, adding A$12.26 million. Market Cap: A$142.86M COSOL Limited, with a market cap of A$142.86 million, demonstrates mixed financial health. Trading at a value price-to-earnings ratio of 16x and offering high-quality earnings, it presents potential value compared to peers. However, its short-term assets (A$32.3M) do not cover long-term liabilities (A$40.7M), and net profit margins have declined from 9.5% to 8.1%. The company's debt is well covered by operating cash flow at 25%, but the dividend yield of 3.04% isn't supported by free cash flows. Recent inclusion in the S&P/ASX All Ordinaries Index highlights its growing recognition in the market. Get an in-depth perspective on COSOL's performance by reading our balance sheet health report here. Gain insights into COSOL's future direction by reviewing our growth report. Reveal the 1,000 hidden gems among our ASX Penny Stocks screener with a single click here. Ready For A Different Approach? Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:ARX ASX:BBN and ASX:COS. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14 hours ago
- Business
- Yahoo
ASX Growth Companies With High Insider Ownership June 2025
As the Australian market faces a slight downturn, influenced by global trade uncertainties and energy developments, investors are keenly observing the ASX 200's movements amid fluctuating international dynamics. In this environment, growth companies with high insider ownership can often be appealing due to their potential for strong alignment between management and shareholder interests, especially when navigating complex market conditions. Name Insider Ownership Earnings Growth Alfabs Australia (ASX:AAL) 10.8% 41.3% Brightstar Resources (ASX:BTR) 11.6% 106.7% Fenix Resources (ASX:FEX) 21.1% 53.4% Acrux (ASX:ACR) 15.6% 106.9% Cyclopharm (ASX:CYC) 11.3% 97.8% Echo IQ (ASX:EIQ) 19.8% 65.9% Newfield Resources (ASX:NWF) 31.5% 72.1% Titomic (ASX:TTT) 11.2% 77.2% Image Resources (ASX:IMA) 20.6% 79.9% Findi (ASX:FND) 29.1% 139.5% Click here to see the full list of 97 stocks from our Fast Growing ASX Companies With High Insider Ownership screener. We're going to check out a few of the best picks from our screener tool. Simply Wall St Growth Rating: ★★★★★☆ Overview: Chrysos Corporation Limited develops and supplies mining technology, with a market cap of A$597.99 million. Operations: Chrysos Corporation Limited generates revenue primarily from its Mining Services segment, amounting to A$55.51 million. Insider Ownership: 17.6% Chrysos is positioned for significant growth with an expected annual revenue increase of 27.8%, outpacing the Australian market's 5.7%. Despite having less than a year of cash runway, its forecasted profitability within three years suggests robust potential. Earnings are anticipated to grow at 58.15% annually, although return on equity remains low at 6.9%. Recent conference presentations indicate active engagement with investors, but no substantial insider trading activity was noted over the past three months. Unlock comprehensive insights into our analysis of Chrysos stock in this growth report. According our valuation report, there's an indication that Chrysos' share price might be on the expensive side. Simply Wall St Growth Rating: ★★★★★★ Overview: Develop Global Limited, along with its subsidiaries, focuses on the exploration and development of mineral resource properties in Australia and has a market cap of A$1.10 billion. Operations: The company generates revenue primarily from its mining services segment, which amounts to A$194.45 million. Insider Ownership: 20.7% Develop Global is set for substantial growth, with revenue projected to rise by 47.5% annually, significantly outpacing the Australian market's 5.7%. The company is expected to achieve profitability within three years, with earnings forecasted to grow at a robust 90.32% per year. Trading at a good value relative to peers and industry benchmarks, Develop Global's return on equity is anticipated to reach a high of 25.5%, underscoring its strong growth potential without recent insider trading activity impacting sentiment. Click to explore a detailed breakdown of our findings in Develop Global's earnings growth report. According our valuation report, there's an indication that Develop Global's share price might be on the cheaper side. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Universal Store Holdings Limited is an Australian company that designs, wholesales, and retails fashion products for men and women, with a market cap of A$596.12 million. Operations: The company generates revenue primarily through its Universal Store segment, which accounts for A$287.13 million, and the CTC segment contributing A$41.29 million. Insider Ownership: 14.1% Universal Store Holdings is positioned for growth, with its revenue expected to increase by 8.8% annually, surpassing the Australian market's 5.7%. Despite trading at 64.3% below fair value estimates, recent substantial insider selling could raise concerns. Earnings are forecasted to grow at 18.48% per year, outpacing the market's 11.8%, though not significantly high by some standards. Analysts anticipate a stock price rise of 27.6%, but dividend sustainability remains questionable with coverage issues present amidst these forecasts and activities. Dive into the specifics of Universal Store Holdings here with our thorough growth forecast report. Our comprehensive valuation report raises the possibility that Universal Store Holdings is priced lower than what may be justified by its financials. Click this link to deep-dive into the 97 companies within our Fast Growing ASX Companies With High Insider Ownership screener. Ready For A Different Approach? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years. Companies discussed in this article include ASX:C79 ASX:DVP and ASX:UNI. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
3 days ago
- Business
- Yahoo
Australia Legal Cannabis Market Forecast Report 2025-2030 - Surge in Demand for Low-Dose CBD and OTC Access
The main market opportunities in the Australian legal cannabis sector are driven by supportive regulatory frameworks, increased medical cannabis prescriptions, and a rising demand for low-dose CBD products. Domestic production and diversified product offerings further enhance growth, positioning Australia as a key cannabis innovation hub. Australian Legal Cannabis Market Dublin, May 30, 2025 (GLOBE NEWSWIRE) -- The "Australia Legal Cannabis Market, By Region, Competition, Forecast & Opportunities, 2020-2030F" has been added to offering. The Australia Legal Cannabis Market was valued at USD 126.32 million in 2024 and is expected to reach USD 420.33 million by 2030, rising at a CAGR of 22.16% This growth is fueled by progressive legislative developments, increasing medical awareness, and broader access initiatives for therapeutic cannabis. Federal and state-level regulatory advancements are fostering a more organized and transparent cannabis sector. The market is experiencing a notable rise in medical cannabis prescriptions, driven by its application in treating chronic pain, anxiety, sleep disorders, and other conditions. Domestic production is also gaining traction as companies invest in localized cultivation and processing infrastructure, aiming to enhance supply chain efficiency and reduce reliance on imports. Support from healthcare providers, coupled with growth in clinical education and research, continues to boost adoption across medical fields. Meanwhile, the industry is evolving through diversification in product offerings - such as oils, capsules, and topicals - and the integration of digital health platforms, positioning Australia as a key regional hub for cannabis innovation and export. Favorable Regulatory Environment and Policy Support A supportive regulatory framework and comprehensive policy measures are key enablers of growth in the Australia Legal Cannabis Market. Since the 2016 legalization of medicinal cannabis, the Australian government has implemented structured systems allowing licensed cultivation, production, and distribution. Agencies like the Therapeutic Goods Administration (TGA) and the Office of Drug Control (ODC) oversee pathways such as the Special Access Scheme (SAS) and the Authorised Prescriber Scheme, facilitating legal, controlled patient access to cannabis treatments when conventional methods fall short. Recent developments, including the reclassification of low-dose CBD as a Schedule 3 substance, reflect a progressive stance aimed at increasing accessibility. Though no products have yet gained OTC approval, this shift highlights the government's intent to broaden access to non-psychoactive cannabis applications. These changes not only enhance patient reach but also encourage foreign investment, support pharmaceutical innovation, and elevate Australia's standing as a regulated and export-ready cannabis market. High Costs of Production and Patient Access The Australia Legal Cannabis Market faces significant hurdles due to the high costs associated with producing pharmaceutical-grade cannabis and the barriers these costs create for patient access. Compliance with strict quality and safety standards necessitates large investments in advanced cultivation technology and quality assurance systems. These costs inflate retail prices, placing a financial burden on patients - particularly since medical cannabis is not covered under the Pharmaceutical Benefits Scheme (PBS). As a result, patients must rely on out-of-pocket payments, limiting affordability and reducing uptake, especially among those needing ongoing treatment. The lack of insurance coverage further exacerbates the issue. Additionally, navigating regulatory processes such as the SAS and securing prescriptions from qualified practitioners can be complex and time-consuming. Limited awareness among medical professionals about cannabis therapies adds to access difficulties. Together, these financial and procedural barriers hinder the market's growth potential and restrict the widespread adoption of cannabis-based treatments. Surge in Demand for Low-Dose CBD and OTC Access A growing consumer interest in wellness and plant-based alternatives is fueling demand for low-dose cannabidiol (CBD) products in the Australian market. This trend gained momentum after the Therapeutic Goods Administration (TGA) reclassified low-dose CBD (up to 150 mg/day) as a Schedule 3 substance, potentially allowing over-the-counter availability without a prescription. While no such products have yet received approval, the regulatory shift signals expanded access to cannabis-derived wellness products aimed at managing mild ailments like anxiety and sleep disorders. This evolving preference is prompting companies to invest in the research and development of clinically validated, standardized formulations that comply with strict safety and efficacy guidelines. As consumers increasingly favor self-directed health solutions, the market is witnessing heightened innovation and competition among players aiming to secure a share in this emerging OTC segment. Report Scope Key Market Players: Cann Group Limited Zelira Therapeutics AusCann Group Holdings Ltd. Bod Australia Althea Group ECOFIBRE Botanix Pharmaceuticals EPSILON Little Green Pharma Incannex Australia Legal Cannabis Market, By Source: Hemp Marijuana Australia Legal Cannabis Market, By Derivatives: CBD THC Others Australia Legal Cannabis Market, By Cultivation: Indoor Cultivation Greenhouse Cultivation Outdoor Cultivation Australia Legal Cannabis Market, By End Use: Industrial Use Medical Use Recreational Use Australia Legal Cannabis Market, By Region: Victoria & Tasmania Queensland Western Australia Northern Territory & Southern Australia Australia Capital Territory & New South Wales Key Attributes: Report Attribute Details No. of Pages 84 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $126.32 Million Forecasted Market Value (USD) by 2030 $420.33 Million Compound Annual Growth Rate 22.1% Regions Covered Australia For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Australian Legal Cannabis Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
3 days ago
- Business
- Yahoo
Australia Legal Cannabis Market Forecast Report 2025-2030 - Surge in Demand for Low-Dose CBD and OTC Access
The main market opportunities in the Australian legal cannabis sector are driven by supportive regulatory frameworks, increased medical cannabis prescriptions, and a rising demand for low-dose CBD products. Domestic production and diversified product offerings further enhance growth, positioning Australia as a key cannabis innovation hub. Australian Legal Cannabis Market Dublin, May 30, 2025 (GLOBE NEWSWIRE) -- The "Australia Legal Cannabis Market, By Region, Competition, Forecast & Opportunities, 2020-2030F" has been added to offering. The Australia Legal Cannabis Market was valued at USD 126.32 million in 2024 and is expected to reach USD 420.33 million by 2030, rising at a CAGR of 22.16% This growth is fueled by progressive legislative developments, increasing medical awareness, and broader access initiatives for therapeutic cannabis. Federal and state-level regulatory advancements are fostering a more organized and transparent cannabis sector. The market is experiencing a notable rise in medical cannabis prescriptions, driven by its application in treating chronic pain, anxiety, sleep disorders, and other conditions. Domestic production is also gaining traction as companies invest in localized cultivation and processing infrastructure, aiming to enhance supply chain efficiency and reduce reliance on imports. Support from healthcare providers, coupled with growth in clinical education and research, continues to boost adoption across medical fields. Meanwhile, the industry is evolving through diversification in product offerings - such as oils, capsules, and topicals - and the integration of digital health platforms, positioning Australia as a key regional hub for cannabis innovation and export. Favorable Regulatory Environment and Policy Support A supportive regulatory framework and comprehensive policy measures are key enablers of growth in the Australia Legal Cannabis Market. Since the 2016 legalization of medicinal cannabis, the Australian government has implemented structured systems allowing licensed cultivation, production, and distribution. Agencies like the Therapeutic Goods Administration (TGA) and the Office of Drug Control (ODC) oversee pathways such as the Special Access Scheme (SAS) and the Authorised Prescriber Scheme, facilitating legal, controlled patient access to cannabis treatments when conventional methods fall short. Recent developments, including the reclassification of low-dose CBD as a Schedule 3 substance, reflect a progressive stance aimed at increasing accessibility. Though no products have yet gained OTC approval, this shift highlights the government's intent to broaden access to non-psychoactive cannabis applications. These changes not only enhance patient reach but also encourage foreign investment, support pharmaceutical innovation, and elevate Australia's standing as a regulated and export-ready cannabis market. High Costs of Production and Patient Access The Australia Legal Cannabis Market faces significant hurdles due to the high costs associated with producing pharmaceutical-grade cannabis and the barriers these costs create for patient access. Compliance with strict quality and safety standards necessitates large investments in advanced cultivation technology and quality assurance systems. These costs inflate retail prices, placing a financial burden on patients - particularly since medical cannabis is not covered under the Pharmaceutical Benefits Scheme (PBS). As a result, patients must rely on out-of-pocket payments, limiting affordability and reducing uptake, especially among those needing ongoing treatment. The lack of insurance coverage further exacerbates the issue. Additionally, navigating regulatory processes such as the SAS and securing prescriptions from qualified practitioners can be complex and time-consuming. Limited awareness among medical professionals about cannabis therapies adds to access difficulties. Together, these financial and procedural barriers hinder the market's growth potential and restrict the widespread adoption of cannabis-based treatments. Surge in Demand for Low-Dose CBD and OTC Access A growing consumer interest in wellness and plant-based alternatives is fueling demand for low-dose cannabidiol (CBD) products in the Australian market. This trend gained momentum after the Therapeutic Goods Administration (TGA) reclassified low-dose CBD (up to 150 mg/day) as a Schedule 3 substance, potentially allowing over-the-counter availability without a prescription. While no such products have yet received approval, the regulatory shift signals expanded access to cannabis-derived wellness products aimed at managing mild ailments like anxiety and sleep disorders. This evolving preference is prompting companies to invest in the research and development of clinically validated, standardized formulations that comply with strict safety and efficacy guidelines. As consumers increasingly favor self-directed health solutions, the market is witnessing heightened innovation and competition among players aiming to secure a share in this emerging OTC segment. Report Scope Key Market Players: Cann Group Limited Zelira Therapeutics AusCann Group Holdings Ltd. Bod Australia Althea Group ECOFIBRE Botanix Pharmaceuticals EPSILON Little Green Pharma Incannex Australia Legal Cannabis Market, By Source: Hemp Marijuana Australia Legal Cannabis Market, By Derivatives: CBD THC Others Australia Legal Cannabis Market, By Cultivation: Indoor Cultivation Greenhouse Cultivation Outdoor Cultivation Australia Legal Cannabis Market, By End Use: Industrial Use Medical Use Recreational Use Australia Legal Cannabis Market, By Region: Victoria & Tasmania Queensland Western Australia Northern Territory & Southern Australia Australia Capital Territory & New South Wales Key Attributes: Report Attribute Details No. of Pages 84 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $126.32 Million Forecasted Market Value (USD) by 2030 $420.33 Million Compound Annual Growth Rate 22.1% Regions Covered Australia For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Australian Legal Cannabis Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
